Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Liver Disease: early-phase trial registry
1 of 15 indexed Liver Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 1 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Liver Disease: 15 US clinical trials tracked, 1 recruiting.
Liver Disease is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), running 5 of these trials.
Enrollment posture brief
Registry condition liver-disease
OPEN 1 | RECR 7% | LATE 2 | EARLY 5 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Macular Edema (7% recruiting · 15 trials)
Liver Disease lists 1 open slots (7% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Liver Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Liver Disease is recruiting below its size-band peers.
1 of 15 indexed trials (6.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Liver Disease research.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) accounts for 5 of 15 trials (33.3%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Liver Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Liver Disease splits between interventional and observational designs.
7 interventional and 8 observational studies make up this index (46.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Evaluation of Patients With Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00001971
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
University of North Carolina, Chapel Hill
NCT00804583
Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM
Baylor Research Institute
NCT02070315
Genetics of Hepatitis C Virus Infection
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00005657
Pediatric Liver Database
Medical College of Wisconsin
NCT00677625
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
Merck Sharp & Dohme
NCT06482112
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02520609
Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
University of Colorado, Denver
NCT02366845
Hepatic Impairment Study
Bayer
NCT00829231
Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT02311348
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Genfit
NCT03765671
Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function
Cumberland Pharmaceuticals
NCT00851227
A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects
NicOx
NCT00621881
Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Baylor College of Medicine
NCT01988753
Gabapentin to Treat Itch in Patients With Liver Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00058890
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Liver Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Liver Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Liver Disease page
15 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Liver Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors the most Liver Disease trials on record, review their full trial history before evaluating a specific study. See National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Disease condition card totals 15 registered trials; most-linked intervention conivaptan hydrochloride; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.